India, July 30 -- Bharat Parenterals announced that its subsidiary, Innoxel Lifesciences, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its finished dosage manufacturing facility in Vadodara, Gujarat.This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025. The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Liquid Injectables and Oral Liquids.With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection.This milestone reinforces Innoxel's commitment to glo...